Prognostic Significance of baseline systemic inflammation markers in PD-L1-negative advanced non-small cell lung cancer patients treated with the BRICS sequential regimen.

ABSTRACT:

Background

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with PD-L1-negative tumors exhibiting poor response to immune checkpoint inhibitors (ICIs) and chemotherapy. The multimodal BRICS regimen-integrating stereotactic body radiotherapy (SBRT), Bifidobacterium supplementation, low-dose chemotherapy, and PD-1 blockade-offers a promising approach for this high-risk subgroup. This study evaluates the prognostic role of baseline systemic inflammation markers in this context.

Methods

A retrospective analysis included 23 PD-L1-negative (TPS <1%), EGFR/ALK wild-type advanced NSCLC patients treated with BRICS (2018-2024). Pretreatment markers (e.g., CLR, LDH) were assessed from blood samples. The sequential regimen involved: (1) SBRT (24 Gy/

SUBMITTER: Chen J 

PROVIDER: S-EPMC12728061 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature